​
​

Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRMY Stock Forecast

Harmony Biosciences stock forecast is as follows: an average price target of $48.86 (represents a 49.01% upside from HRMY’s last price of $32.79) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

HRMY Price Target

The average price target for Harmony Biosciences (HRMY) is $48.86 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $61.00 to $28.00. This represents a potential 49.01% upside from HRMY's last price of $32.79.

HRMY Analyst Ratings

Buy

According to 8 Wall Street analysts, Harmony Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for HRMY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).

Harmony Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Corinne JenkinsGoldman Sachs$28.00$41.49-32.51%-14.61%
Oct 10, 2024Graig SuvannavejhMizuho Securities$52.00$33.6054.76%58.58%
Sep 10, 2024Ashwani VermaUBS$56.00$36.8951.80%70.78%
Aug 08, 2024Graig SuvannavejhMizuho Securities$42.00$33.5525.19%28.09%
Jun 24, 2024Francois BriseboisOppenheimer$56.00$30.3984.27%70.78%
May 01, 2024Ami FadiaNeedham$52.00$30.3771.22%58.58%
Apr 30, 2024Danielle BrillRaymond James$37.00$30.9119.70%12.84%
Oct 14, 2022Chris HowertonJefferies$61.00$47.6328.07%86.03%
Row per page
Go to

The latest Harmony Biosciences stock forecast, released on Oct 30, 2024 by Corinne Jenkins from Goldman Sachs, set a price target of $28.00, which represents a -32.51% decrease from the stock price at the time of the forecast ($41.49), and a -14.61% decrease from HRMY last price ($32.79).

Harmony Biosciences Price Target by Period

1M3M12M
# Anlaysts137
Avg Price Target$28.00$45.33$46.14
Last Closing Price$32.79$32.79$32.79
Upside/Downside-14.61%38.24%40.71%

In the current month, the average price target of Harmony Biosciences stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -14.61% decrease as opposed to Harmony Biosciences's last price of $32.79. This month's average price target is down -38.23% compared to last quarter, and down -39.32% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 30, 2024OppenheimerOutperformOutperformHold
Oct 30, 2024Goldman SachsSellSellHold
Oct 29, 2024UBSBuyBuyHold
Oct 29, 2024Raymond JamesUnderperformUnderperformHold
Oct 02, 2024UBSBuyBuyHold
Sep 12, 2024NeedhamBuyBuyHold
Sep 10, 2024UBSBuyBuyHold
Sep 10, 2024NeedhamUnderperformUnderperformHold
Sep 09, 2024UBS-BuyInitialise
Row per page
Go to

Harmony Biosciences's last stock rating was published by Cantor Fitzgerald on Oct 30, 2024. The company gave HRMY a "Overweight" rating, the same as its previous rate.

Harmony Biosciences Financial Forecast

Harmony Biosciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-------------$160.27M$134.22M$119.13M$128.31M$117.21M$107.03M$85.31M$91.21M$80.73M$73.82M$59.67M$56.29M$45.61M
Avg Forecast$277.53M$265.66M$246.78M$220.79M$233.44M$219.33M$202.54M$182.41M$198.58M$184.07M$172.53M$154.10M$169.02M$147.83M$142.01M$120.14M$127.66M$113.59M$100.73M$88.55M$89.53M$79.90M$68.83M$57.20M$51.89M$40.00M
High Forecast$284.96M$272.77M$253.38M$226.70M$239.68M$225.19M$207.96M$187.89M$202.61M$184.36M$172.53M$158.22M$169.67M$156.89M$145.81M$123.35M$131.08M$113.59M$100.73M$88.55M$89.53M$79.90M$68.83M$57.20M$51.89M$40.00M
Low Forecast$269.55M$258.02M$239.68M$214.44M$226.72M$213.02M$196.72M$179.37M$191.41M$183.77M$172.53M$149.67M$168.37M$139.32M$137.93M$116.68M$123.99M$113.59M$100.73M$88.55M$89.53M$79.90M$68.83M$57.20M$51.89M$40.00M
# Analysts22221114631128544343545454
Surprise %-------------1.08%0.95%0.99%1.01%1.03%1.06%0.96%1.02%1.01%1.07%1.04%1.08%1.14%

Harmony Biosciences's average Quarter revenue forecast for Dec 23 based on 2 analysts is $169.02M, with a low forecast of $168.37M, and a high forecast of $169.67M. HRMY's average Quarter revenue forecast represents a 5.46% increase compared to the company's last Quarter revenue of $160.27M (Sep 23).

Harmony Biosciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts22221114631128544343545454
EBITDA-------------$64.51M$46.90M$46.49M$47.69M$18.02M$39.21M$32.75M$33.42M$-5.85M$20.82M$12.06M$12.14M$10.82M
Avg Forecast$3.19M$3.05M$2.83M$2.53M$2.68M$2.52M$2.33M$2.09M$2.28M$2.11M$1.98M$40.29M$1.94M$1.70M$1.63M$36.63M$34.72M$1.04M$926.09K$28.96M$823.08K$734.59K$632.84K$525.89K$477.04K$8.66M
High Forecast$3.27M$3.13M$2.91M$2.60M$2.75M$2.59M$2.39M$2.16M$2.33M$2.12M$1.98M$48.35M$1.95M$1.80M$1.67M$43.96M$41.67M$1.04M$926.09K$34.75M$823.08K$734.59K$632.84K$525.89K$477.04K$10.39M
Low Forecast$3.09M$2.96M$2.75M$2.46M$2.60M$2.45M$2.26M$2.06M$2.20M$2.11M$1.98M$32.23M$1.93M$1.60M$1.58M$29.30M$27.78M$1.04M$926.09K$23.16M$823.08K$734.59K$632.84K$525.89K$477.04K$6.93M
Surprise %-------------38.01%28.77%1.27%1.37%17.26%42.34%1.13%40.61%-7.96%32.90%22.94%25.45%1.25%

2 analysts predict HRMY's average Quarter EBITDA for Dec 23 to be $1.94M, with a high of $1.95M and a low of $1.93M. This is -96.99% lower than Harmony Biosciences's previous annual EBITDA (Sep 23) of $64.51M.

Harmony Biosciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts22221114631128544343545454
Net Income-------------$38.46M$34.30M$29.48M$48.51M$87.94M$23.53M$21.48M$22.71M$-9.62M$14.12M$7.39M$-208.00K$1.91M
Avg Forecast$69.92M$66.23M$60.68M$51.51M$46.68M$43.96M$41.31M$37.12M$39.78M$38.63M$-96.86K$26.43M$41.95M$38.67M$35.37M$24.03M$23.60M$5.97M$25.89M$18.99M$20.52M$16.11M$10.17M$97.50M$4.41M$1.53M
High Forecast$72.35M$68.54M$62.79M$53.30M$48.30M$45.48M$42.74M$43.81M$49.90M$38.69M$-93.24K$31.72M$44.79M$46.41M$36.60M$28.83M$28.32M$5.97M$25.89M$22.79M$20.52M$16.11M$10.17M$116.99M$4.41M$1.83M
Low Forecast$67.31M$63.76M$58.41M$49.58M$44.93M$42.31M$39.76M$23.73M$29.67M$38.58M$-100.23K$21.14M$40.25M$33.91M$34.05M$19.22M$18.88M$5.97M$25.89M$15.20M$20.52M$16.11M$10.17M$78.00M$4.41M$1.22M
Surprise %-------------0.99%0.97%1.23%2.06%14.73%0.91%1.13%1.11%-0.60%1.39%0.08%-0.05%1.25%

Harmony Biosciences's average Quarter net income forecast for Dec 23 is $41.95M, with a range of $40.25M to $44.79M. HRMY's average Quarter net income forecast represents a 9.07% increase compared to the company's last Quarter net income of $38.46M (Sep 23).

Harmony Biosciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts22221114631128544343545454
SG&A-------------$45.96M$47.34M$44.63M$43.72M$41.80M$42.32M$35.46M$37.31M$33.34M$31.32M$30.05M$30.99M$23.11M
Avg Forecast$843.71M$807.63M$750.22M$671.21M$709.66M$666.76M$615.73M$554.54M$603.69M$559.58M$524.49M$43.63M$513.84M$449.40M$431.72M$39.66M$38.77M$345.31M$306.22M$31.35M$272.16M$242.90M$209.26M$173.89M$157.74M$18.49M
High Forecast$866.28M$829.24M$770.29M$689.17M$728.64M$684.60M$632.21M$571.20M$615.96M$560.48M$524.49M$52.35M$515.82M$476.96M$443.27M$47.59M$46.52M$345.31M$306.22M$37.62M$272.16M$242.90M$209.26M$173.89M$157.74M$22.18M
Low Forecast$819.45M$784.41M$728.65M$651.91M$689.25M$647.59M$598.03M$545.29M$581.89M$558.68M$524.49M$34.90M$511.86M$423.53M$419.31M$31.73M$31.01M$345.31M$306.22M$25.08M$272.16M$242.90M$209.26M$173.89M$157.74M$14.79M
Surprise %-------------0.10%0.11%1.13%1.13%0.12%0.14%1.13%0.14%0.14%0.15%0.17%0.20%1.25%

Harmony Biosciences's average Quarter SG&A projection for Dec 23 is $513.84M, based on 2 Wall Street analysts, with a range of $511.86M to $515.82M. The forecast indicates a 1017.92% rise compared to HRMY last annual SG&A of $45.96M (Sep 23).

Harmony Biosciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts22221114631128544343545454
EPS-------------$0.64$0.57$0.49$0.82$1.48$0.40$0.36$0.39$-0.17$0.25$0.13$-0.00$0.06
Avg Forecast$1.20$1.14$1.04$0.89$0.80$0.76$0.71$0.64$0.68$0.66$-0.00$0.60$0.72$0.67$0.61$0.47$0.58$0.10$0.45$0.29$0.36$0.28$0.18$-0.03$0.08$-0.05
High Forecast$1.25$1.18$1.08$0.92$0.83$0.78$0.74$0.75$0.86$0.67$-0.00$0.60$0.77$0.80$0.63$0.49$0.60$0.10$0.45$0.29$0.36$0.28$0.18$-0.03$0.08$-0.05
Low Forecast$1.16$1.10$1.01$0.85$0.77$0.73$0.68$0.41$0.51$0.66$-0.00$0.60$0.69$0.58$0.59$0.45$0.56$0.10$0.45$0.29$0.36$0.28$0.18$-0.03$0.08$-0.05
Surprise %-------------0.96%0.94%1.04%1.40%14.27%0.89%1.23%1.09%-0.61%1.42%-4.87%-0.05%-1.35%

According to 2 Wall Street analysts, Harmony Biosciences's projected average Quarter EPS for Dec 23 is $0.72, with a low estimate of $0.69 and a high estimate of $0.77. This represents a 12.81% increase compared to HRMY previous annual EPS of $0.64 (Sep 23).

Harmony Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$1.72$33.861868.60%Buy
GOSSGossamer Bio$0.70$3.75435.71%Buy
INZYInozyme Pharma$2.79$14.67425.81%Buy
FENCFennec Pharmaceuticals$4.64$15.75239.44%Buy
PLRXPliant Therapeutics$12.73$39.71211.94%Buy
GPCRStructure Therapeutics$32.71$92.40182.48%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
REPLReplimune Group$11.23$24.20115.49%Buy
SNDXSyndax Pharmaceuticals$15.95$34.30115.05%Buy
VRDNViridian Therapeutics$19.79$37.9291.61%Buy
KRONKronos Bio$0.86$1.6389.53%Buy
KROSKeros Therapeutics$54.14$102.6089.51%Buy
IDYAIDEAYA Biosciences$25.54$46.5882.38%Buy
HRMYHarmony Biosciences$32.79$48.8649.01%Buy
EWTXEdgewise Therapeutics$31.95$45.0040.85%Buy
JANXJanux Therapeutics$48.96$61.2025.00%Buy
PTGXProtagonist Therapeutics$40.65$50.0023.00%Buy
NUVLNuvalent$91.17$111.5722.38%Buy
TVTXTravere Therapeutics$17.86$21.7521.78%Buy
RVMDRevolution Medicines, Inc. Warrant$57.07$60.636.24%Buy
VRNAVerona Pharma$38.85$33.86-12.84%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

HRMY Forecast FAQ

Is Harmony Biosciences a good buy?

Yes, according to 8 Wall Street analysts, Harmony Biosciences (HRMY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of HRMY's total ratings.

What is HRMY's price target?

Harmony Biosciences (HRMY) average price target is $48.86 with a range of $28 to $61, implying a 49.01% from its last price of $32.79. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Harmony Biosciences stock go up soon?

According to Wall Street analysts' prediction for HRMY stock, the company can go up by 49.01% (from the last price of $32.79 to the average price target of $48.86), up by 86.03% based on the highest stock price target, and down by -14.61% based on the lowest stock price target.

Can Harmony Biosciences stock reach $50?

HRMY's highest twelve months analyst stock price target of $61 supports the claim that Harmony Biosciences can reach $50 in the near future.

What is Harmony Biosciences's current price target trend?

1 Wall Street analyst forecast a $28 price target for Harmony Biosciences (HRMY) this month, down -14.61% from its last price of $32.79. Compared to the last 3 and 12 months, the average price target increased by 38.24% and increased by 40.71%, respectively.

What are Harmony Biosciences's analysts' financial forecasts?

Harmony Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $837.71M (high $860.72M, low $815.83M), average EBITDA is $9.62M (high $9.88M, low $9.37M), average net income is $169.06M (high $180.34M, low $150.74M), average SG&A $2.55B (high $2.62B, low $2.48B), and average EPS is $2.91 (high $3.1, low $2.59). HRMY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.01B (high $1.04B, low $981.7M), average EBITDA is $11.6M (high $11.91M, low $11.27M), average net income is $248.34M (high $256.98M, low $239.06M), average SG&A $3.07B (high $3.15B, low $2.98B), and average EPS is $4.27 (high $4.42, low $4.11).

Did the HRMY's actual financial results beat the analysts' financial forecasts?

Based on Harmony Biosciences's last annual report (Dec 2022), the company's revenue was $437.86M, beating the average analysts forecast of $430.53M by 1.70%. Apple's EBITDA was $120.36M, beating the average prediction of $65.65M by 83.33%. The company's net income was $181.47M, beating the average estimation of $74.46M by 143.73%. Apple's SG&A was $163.3M, missing the average forecast of $721.65M by -77.37%. Lastly, the company's EPS was $3.14, beating the average prediction of $1.43 by 119.44%. In terms of the last quarterly report (Sep 2023), Harmony Biosciences's revenue was $160.27M, beating the average analysts' forecast of $147.83M by 8.42%. The company's EBITDA was $64.51M, beating the average prediction of $1.7M by 3701.18%. Harmony Biosciences's net income was $38.46M, missing the average estimation of $38.67M by -0.54%. The company's SG&A was $45.96M, missing the average forecast of $449.4M by -89.77%. Lastly, the company's EPS was $0.64, missing the average prediction of $0.666 by -3.84%